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Posttranslational modiﬁcationMembrane type 1 (MT1)-matrix metalloproteinase (MT1-MMP) is a membrane-tethered MMP that has been
shown to play a key role in promoting cancer cell invasion. MT1-MMP is highly expressed in bonemetastasis of
prostate cancer (PC) patients and promotes intraosseous tumor growth of PC cells in mice. The majority of
metastatic prostate cancers harbor loss-of-function mutations or deletions of the tumor suppressor PTEN
(phosphatase and tensin homologue deleted on chromosome ten). However, the role of PTEN inactivation in
MT1-MMP expression in PC cells has not been examined. In this study, prostate epithelial cell lines derived from
mice that are either heterozygous (PTEN+/-) or homozygous (PTEN−/−) for PTEN deletion or harboring a wild-
type PTEN (PTEN+/+) were used to investigate the expression of MT1-MMP. We found that biallelic loss of PTEN
is associated with posttranslational regulation of MT1-MMP protein in mouse PC cells. PTEN−/− PC cells display
higher levels of MT1-MMP at the cell surface when compared to PTEN+/+ and PTEN+/− cells and consequently
exhibited enhanced migratory and collagen-invasive activities. MT1-MMP displayed by PTEN−/− cells is
differentially O-glycosylated and exhibits a slow rate of turnover. MT1-MMP expression in PTEN−/− cells is
under control of the PI3K/AKT signaling pathway, as determined using pharmacological inhibitors. Interestingly,
rapamycin, anmTOR inhibitor, upregulatesMT1-MMP expression in PTEN+/+ cells via PI3K activity. Collectively,
these data in a mouse prostate cell system uncover for the ﬁrst time a novel and complex relationship between
PTEN loss-mediated PI3K/AKT activation and posttranslational regulation ofMT1-MMP, whichmay play a role in
PC progression.logue deleted on chromosome
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The matrix metalloproteinase (MMP) family of zinc-dependent
endopeptidases comprises secreted and membrane-anchored pro-
teases that are major mediators of cellular proteolysis [1]. MMPs play
key roles in normal and pathological conditions due to their ability to
accomplish the proteolytic processing of multiple proteins. The
members of the membrane-anchored MMP subfamily, referred to asmembrane-type MMPs (MT-MMPs), comprise type I transmembrane
and glycosylphosphatidylinositol (GPI)-containing MMPs that, by
their speciﬁc structural organization and subcellular localization, play
a pivotal role in pericellular proteolysis [2]. Membrane-anchoring
confers these MMPs with a unique set of regulatory mechanisms that
serve to maintain a pool of active protease at the cell surface including
internalization, autocatalytic processing, and ectodomain shedding
[3]. In addition, there is evidence that posttranslational modiﬁcations
such as O-glycosylation, homodimerization, phosphorylation, and/or
palmitoylation can inﬂuence MT-MMP function by regulating intra-
cellular trafﬁcking, insertion into membrane microdomains, stability,
endocytosis, substrate interaction, and/or inhibitor binding [3–11].
In cancer, members of theMT-MMP subfamily have been shown to
promote tumor cell migration and invasion through extracellular
matrices. In particular, the transmembrane MT-MMPs, MT1-
(MMP14), MT2-(MMP15), and MT3-(MMP16) MMP, were described
as a triad of MMPs that support the invasive behavior of cancer cells
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through interstitial collagen by accomplishing proteolysis of collagen I
[13]. Consistently, MT1-MMP expression promotes intraosseous
growth of human prostate cancer (PC) cells and induces an osteolytic
response in a mouse model of PC intraosseous growth [14]. Human PC
cell lines expressing MT1-MMP exhibit enhanced migratory and
invasive activity in vitro and increased tumorigenicity and metastatic
potential in mice [15–18]. Furthermore, MT1-MMP was shown to
induce an epithelial-to-mesenchymal transition phenotype when
ectopically expressed in LNCaP cells [19]. These experimental results
together with evidence showing expression of MT1-MMP in primary
tumors [20–22] and in bone metastasis [14] of PC suggest a role for
MT1-MMP in PC progression.
PTEN (phosphatase and tensin homologue deleted on chromo-
some ten) is a phosphatase that its main function is to dephosphor-
ylate phosphatidylinositol 3,4,5-trisphosphate (PIP3), generated by
phosphoinositide 3-kinase (PI3K), which results in the formation of
PIP2. Dephosphorylation of PIP3 by PTEN negatively regulates the
activation of the AKT/Pkb pathway whereas inactivation of PTEN
leads to accumulation of PIP3, which promotes AKT phosphorylation.
Active AKT modulates multiple downstream effectors leading to
protein synthesis, cell proliferation, and cell survival. Consequently,
deregulated activation of the PI3K/AKT pathway upon loss of PTEN
function can contribute to cancer development and progression.
Accumulating evidence indicate that loss of heterozygosity and
somatic mutations of the tumor suppressor gene PTEN is one of the
most frequent genetic alterations found in PC patients [23–25]. PTEN
deletions are associated with 15–30% of localized cancers [26,27] and
with poor clinical outcome [28,29]. The rate of PTEN mutations
increases to more than 50% in metastatic PC [30]. Consistent with
these ﬁndings, homozygous, conditional deletion of PTEN by Cre
recombinase under control of the probasin or prostate speciﬁc antigen
(PSA) promoter in mouse prostate epithelium promotes PC develop-
ment and invasion closely recapitulating the stages of human prostate
cancer progression [31,32]. Therefore, these mouse models have been
useful in investigating some of the cellular andmolecularmechanisms
contributing to PC progression initiated by loss of PTEN function. With
this in mind, we set to investigate the consequences of PTEN loss on
expression of transmembrane MT-MMPs, with focus on MT1-MMP, in
prostate tissues and prostate epithelial cell lines derived from wild-
type mice and mice with prostate-speciﬁc deletion (heterozygous or
homozygous) of PTEN [33]. The data presented here show that loss of
PTEN in mouse PC cells is associated with a differential proﬁle of
secreted and membrane-tethered MMPs, in particular, gelatinases
and MT-MMPs (MT1-, MT2-, and MT3-MMP). These data also show
that activation of the PI3K/AKT pathway upon loss of PTEN in mouse
prostate epithelial cells is associated with increased expression of
MT1-MMP at the cell surface andwith differential O-glycosylation and
reduced turnover of the protease.
2. Materials and methods
2.1. Reagents and antibodies
LY 294,002, PD 98,059, rapamycin, cycloheximide, mitomycin C,
benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BGN), and con-
canavalin A (ConA) were obtained from Sigma (St. Louis, MO). AKT
inhibitor IV was obtained from Calbiochem (San Diego, CA). All other
chemicals were of highest available grade and were purchased from
standard sources. A mouse monoclonal antibody (mAb) against the
catalytic domain of MT1-MMP (3G4), which cross reacts with mouse
MT1-MMP, was a kind gift from Dr. Alex Strongin (Burnham Research
Institute, La Jolla, CA) or was purchased from Millipore (Billerica, MA,
cat. no. MAB1767). Rabbit polyclonal antibody (pAb) against MT1-
MMP cytosolic domain (cat. no. ab28209) was obtained from Abcam
(Cambridge, MA). A pAb against MT3-MMP (pAb318) was raisedagainst a synthetic peptide derived from the hinge region of MT3-
MMP [34] and cross reacts with both human and mouse MT3-MMP
(unpublished data). Mouse IgG, TrueBlot™ ULTRA, was purchased
from eBioscience (cat. no. 18-8817-38, San Diego, CA). The mAb
against β-actin was obtained from Sigma (St. Louis, MO). Antibodies
to pAkt T308 (cat. no. 9275S), pAkt S473 (cat. no. 9271S), total Akt
(cat. no. 9272), phosphorylated p70 S6 kinase T389 (cat. no. 9205),
and total p70 S6 kinase (cat. no. 9202) were all obtained from Cell
Signaling (Danvers, CA). Rat mAb against mouse transferrin receptor
(cat. no. Sc-59112) and goat anti-Rat secondary antibody (cat. no. Sc-
2006) were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA).
2.2. Cell lines
Cells were isolated from mice harboring a prostate-speciﬁc
deletion of ﬂoxed PTEN in prostate epithelium that was achieved by
expressing Cre recombinase under the control of a probasin promoter
(PB). Mouse genotypes are PtenloxP/lox;PPB-cre4−/− (wild-type),
PtenloxP/+;PB-cre4T/− (heterozygous), and PtenloxP/lox;PPB-cre4T/
− (homozygous) and referred to as PTEN+/+, PTEN+/−, and PTEN−/−,
respectively, as described [33]. PTEN−/− and PTEN+/−mouse prostate
epithelial cells were isolated from anterior prostates of 8- to 10-week-
old corresponding mice [33] using the method previously described
[35]. Ptenlox/lox cells were isolated from anterior prostates of 8-week-
old mice and were referred to here as PTEN+/+ cells. Cells were
clonally selected using serial dilution method [36] and PTEN status
was conﬁrmed by genotyping and Western blotting. Three distinct
clones were isolated for each cell type. Detailed characterization of
these mouse cell lines is the focus of another manuscript (Chen Y-Q et
al., under preparation). The mouse cell lines were cultured in
advanced Dulbecco's modiﬁed Eagle's medium (DMEM) (Invitrogen,
Carlsbad, MA) supplemented with 5% fetal bovine serum (FBS)
(Invitrogen), L-glutamine (Invitrogen), and penicillin/streptomycin
(Invitrogen). HT1080 cells were obtained from the American Type
Culture Collection (ATCC, Rockville, MD) and were cultured in DMEM
supplemented with 10% FBS and antibiotics.
2.3. Semiquantitative RT–PCR
Total RNA was extracted with RNeasy® mini kit (Qiagen, Valencia,
CA), according to the manufacturer's instructions. RT–PCR was
performed with 2 μg of each total RNA sample, collected from cells
growing in complete media, using SuperScript™ III reverse transcrip-
tase (Invitrogen) to synthesize cDNA and subsequently Taq DNA
polymerase (Invitrogen) was used to perform ampliﬁcation of DNA.
The sequences of the primers (IDT, Coralville, IA) for mouse PTEN,
MMPs, and TIMPs are provided in Supplemental Table 1. The
housekeeping GAPDH mRNA was used as an internal control. The
ampliﬁed fragments were resolved by 2% agarose gels and detected by
ethidium bromide staining.
2.4. Real-time PCR
RNA was collected from cells growing in complete media. The
sequence of the primers speciﬁc for mouse MT1-, MT2-, and MT3-
MMP and GAPDH are described in Supplemental Table 1. Real-time
PCR was performed on 50 ng of cDNA using the ABsolute Blue QPCR
SYBR Green master mix kit according to the manufacturer's protocol
(Thermo Scientiﬁc, Rockford, IL). PCR conditions included polymerase
activation at 95 °C for 10 min followed by 40 cycles at 95 °C for 30 s,
55 °C for 30 s, and 72 °C for 30 s. Each assay included a negative
control (DEPC-treated water; Ambion), a no-template control. The
threshold cycle (Ct) of each sample was recorded as a quantitative
measure of the amount of PCR product in the sample using a
Stratagene (La Jolla, CA) MX 3000P™ PCR machine. The MT1-, MT2-,
1289S. Kim et al. / Biochimica et Biophysica Acta 1803 (2010) 1287–1297and MT3-MMP signals were normalized against the relative quantity
of human GAPDH, and the relative amount of MT-MMPs' mRNA was
expressed as the percentage of GAPDH. Data processing and statistical
analyses were performed using Microsoft Excel (Microsoft Corp.,
Redmond, WA).
2.5. Immunoblot analyses
Cultured cells were solubilized with ice-cold lysis buffer (25 mM
Tris–HCl [pH 8.0], 100 mM NaCl, 1% IGEPAL CA-630, 5 mM EDTA)
supplemented with protease inhibitor cocktail without EDTA (Com-
plete, Mini, EDTA-free, Roche, Indianapolis, IN). For immunoblot
analyses of phosphorylated proteins, the cells were lysed with ice-
cold RIPA buffer (0.05 M Tris–HCl, pH 7.4, 0.15 M NaCl, 0.25%
deoxycholic acid, 1% NP-40, 1 mM EDTA) supplemented with 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 2 mM sodium metavanadate
(NaVO3), 1 mM sodium ﬂuoride (NaF), and protease inhibitor
cocktail. The protein concentration in the lysates was determined by
the BCA procedure (Thermo Scientiﬁc). An aliquot of each lysate was
mixed with Laemmli 4× SDS-sample buffer with 1% β-mercaptoetha-
nol, boiled (95 °C, 5 min), and resolved by 10% or 7.5% SDS–PAGE
(depending on the experiment) followed by immunoblot analyses
using various antibodies. Tissue lysates obtained from prostates
isolated from wild-type and PTEN knock-out mice were provided by
Dr. Yong Chen (Wake Forest University) and prepared as previously
described [33]. A total of 35 μg of tumor lysates and 60 μg of normal
lysateswere used for detection ofMT1-MMP by immunoblotting. Trial
experiments showed that a higher amount of protein was required to
clearly detect MT1-MMP in normal prostate lysates and therefore
accurately determine its molecular mass relative to MT1-MMP
expressed in prostate tumor lysates. Brieﬂy, normal and tumor
prostate lysates were incubated (4 °C, overnight) with 30 μl of Protein
G agarose beads (Thermo Scientiﬁc) to remove endogenous mouse
IgG. After a brief centrifugation (10,000×g, 3 min) at 4 °C, the
supernatants were collected, mixed with Laemmli SDS sample buffer,
and resolved by 8% SDS–PAGE under reducing conditions. The protein
was then subjected to immunoblot analyses using the mAb MAB1767
(3G4), which was used at 1:1000 dilution. The blots were then
incubated (room temperature, 90 min) with a 1:2000 dilution of the
TrueBlot™ ULTRA antibody against mouse IgG (eBioscience) followed
by ECL detection of the antigen.
2.6. Cell surface biotinylation
Cells in six-well plates were treated with the cell impermeable EZ-
link-sulfo-NHS-biotin (Thermo Scientiﬁc), as described previously
[37]. The cells were then lysed with 0.2 ml/well of cold lysis buffer on
ice. After a brief centrifugation (15 min, 16,000×g), equal protein
amounts of the supernatants were incubated with immobilized
neutravidin protein beads (Thermo Scientiﬁc) at 4 °C, overnight. The
beads were washed ﬁve times with harvest buffer (0.5% SDS, 60 mM
Tris–HCl, pH 7.5, 2 mM EDTA) supplemented with 2.5% Triton X-100
(ﬁnal concentration), and the biotinylated proteins were eluted with
Laemmli 2× SDS sample buffer, boiled, and resolved by reducing 10%
SDS–PAGE followed by transfer to a nitrocellulose membrane. The
proteins were detected with anti-MT1-MMP or anti-transferrin
receptor antibodies.
2.7. Immunoprecipitation
Cells were solubilized with cold lysis buffer as described above.
After determination of protein concentration, 0.5 mg of protein from
each lysates were incubated (4 °C, overnight) with either 5 μg of pAb
ab28209 against the cytosolic domain of MT1-MMP or non-immuner-
abbit IgG in lysis buffer. The mixtures were then incubated (4 °C, 4 h)
with Protein A conjugated agarose beads (Thermo Scientiﬁc). Thebound proteins were eluted with Laemmli SDS sample buffer, boiled,
and resolved by reducing 7.5% SDS–PAGE followed by immunoblot
analysis using mAb 3G4 to MT1-MMP.
2.8. MT1-MMP deglycosylation and turnover
For assessment of MT1-MMP O-glycosylation, the cells were
incubated (48 h, 37 °C) with 2 mM of benzyl 2-acetamido-2-deoxy-
α-D-galactopyranoside (BGN) in serum-free media followed by lysis
with ice-cold lysis buffer. The lysates were then subjected to
immunoblot analyses as described above. For evaluation of MT1-
MMP turnover, the cells were incubated with 50 μg/ml of cyclohex-
imide (CHX) in complete media, and at each designated time point
(0–8 h), the cells were lysed with ice-cold lysis buffer. The lysates
were then resolved by reducing 10% SDS–PAGE followed by
immunoblot analyses. Densitometric analyses of the bands in the
blots were performed with ImageJ Software (Version: 1.42q, by
Wayne Rasband, NIH, Bethesda, MD) and represented in graphs as
percentage of control: 100%, time zero.
2.9. Pro-MMP-2 activation
PTEN+/+, PTEN−/−, and HT1080 cells were treated with 10 μg/ml
of ConA overnight in serum-freemedia. The cells were then lyses with
ice-cold lysis buffer without EDTA, and the lysates were clariﬁed by
centrifugation and mixed with Laemmli sample buffer without
reducing agents and heating. Pro-MMP-2 activation was monitored
by gelatin zymography, as described previously [38].
2.10. Cell migration and invasion assays
Migration was assessed using a scratch wound assay. Brieﬂy,
conﬂuent cultures of PTEN+/+ and PTEN−/− cells on six-well plates
were gently scratched with a sterile yellow pipette tip and incubated
in completemedia supplementedwith 5 μg/mlmitomycin C to inhibit
cell proliferation. After 8 h of incubation at 37 °C, the cultures were
photographed. Invasion assays using collagen type I were performed
essentially as described [39]. Brieﬂy, a solution of 2.7 mg/ml (ﬁnal
concentration) of puriﬁed rat type I collagen (BD Bioscience, San Jose,
CA) in 0.02 N acetic acid was prepared as described by the
manufacturer. The collagen solution (1 ml/well) was then poured
into the inserts of Transwell® six-well plate (Corning), and the plates
were incubated (1 h, 37 °C) to allow formation of a gel. Cells (1.5×105
cells/well) were seeded in complete medium on top of the collagen
layer. The plates were placed in a tissue culture incubator at 37 °C and
incubated for 14 days with media changes every other day. Some
wells received 5 μM BB-94 at the time of cell seeding, which was
freshly added every other day. At the end of the incubation period, the
media were removed, and the gels were ﬁxed with 4% paraformal-
dehyde and frozen in Tissue-Tek® OCT™ Compound (Sakura Finetek
USA, Inc., Torrance, CA) at −80 °C. Five-micrometer-thick frozen
sections were obtained from each gel, and toluidine blue staining was
performed for microscopic evaluation.
2.11. Treatment with pharmacological inhibitors
Cells at 80% conﬂuence were treated with various doses of LY
294,002, PD 98,059, Akt inhibitor IV, or rapamycin. Brieﬂy, cells were
plated in advanced DMEM supplemented with 5% FBS in either six-
well plates or 60-mm dishes and were allowed to adhere for 18 h. The
cells were then washed with warm PBS and then incubated in serum-
free advanced DMEMmedia supplemented with LY 294,002 (0, 25, or
50 μM ﬁnal concentration), PD 98,059 (0, 25, or 50 μM ﬁnal
concentration), Akt inhibitor IV (0, 1, or 5 μM ﬁnal concentration)
for 18 h, or rapamycin (0, 5, or 10 nM ﬁnal concentration) for 48 h. In
other experiment, serum-starved PTEN−/− cells in six-well plates
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98,059 (25 μM) for 18 h in serum-freemedia. Rapamycin (10 nM)was
then added to some wells containing cells that were treated or not
with LY 294,002 or PD 98,059 for an additional 18 h of incubation. At
the end of the treatments, the cells were lysed for immunoblot
analyses, as described above. Lysates were examined for MT1-MMP,
pAkt (T308), total Akt, phospho p70 S6 kinase (T389), total p70 S6
kinase, and β-actin using speciﬁc antibodies. Cells in duplicate wells,
for each treatment condition, were extracted for total RNA isolation,
as described previously.
3. Results
3.1. PTEN loss in mouse prostate epithelial cells is associated with
differential expression proﬁle of MT-MMPs and enhanced
gelatinase expression
To investigate the relationship between PTEN loss and MT-MMP
expression in prostate cancer, we utilized immortalized prostate
epithelial cells derived from PTEN+/+, PTEN+/−, and PTEN−/− mice
bearing a prostate-speciﬁc PTEN deletion in the epithelium. As shown
in Supplemental Fig. 1, semiquantitative PCR analyses showed a
differential proﬁle of MT-MMPs in these cells. While the three cell
lines express relatively similar levels of MT1-MMP, loss of PTEN was
associated with down-regulation of MT2-MMP and up-regulation of
MT3-MMPmRNA, under the experimental conditions. No expression
of MT5-MMP or the GPI-anchored MT-MMPs (MT4- and MT6-MMP)
was detected in either of the cell lines (data not shown). Biallelic loss
of PTEN is also associated with up-regulation of gelatinases, MMP-2
and MMP-9. mRNAs for the secreted mouse collagenases, MMP1a,
MMP-1b, and MMP-13, were not detected in any of these cell lines,
under these conditions (Supplemental Fig. 1). Analyses of TIMP
mRNAs showed that both TIMP-1 and TIMP-3 were upregulated in
PTEN+/− and PTEN−/− cells when compared to PTEN+/+ cells. In
contrast, no signiﬁcant changes were observed in TIMP-2 mRNA.
TIMP-4mRNAwas not detected in any of the cell lines (Supplemental
Fig. 1). Since MT1-, MT2-, and MT3-MMP have been shown to
represent a triad of MMPs that drive the invasive phenotype of
cancer cells [12], the levels ofmRNA expression of theseMT-MMPs in
PTEN+/+ and PTEN−/− cells were further quantiﬁed by real-time PCR
(Fig. 1A). These results were in general agreement with the semi-
quantitative PCR (Supplemental Fig. 1) and showed thatmRNA levels
of MT1-MMP did not differ signiﬁcantly in PTEN+/+ and PTEN−/−
cells. In contrast, loss of PTEN correlated with enhanced expression
of MT3-MMPmRNA and down-regulation of MT2-MMPmRNA. Next,
we examined the protein levels of MT1-MMP by immunoblotting inFig. 1. Differential expression of MT-MMP mRNA and MT1-MMP protein in mouse prostate
PTEN−/− (white bar) cells cultured in complete media were used for cDNA synthesis and sub
gene was normalized by the GAPDH Ct value. Results shown are representative of two inde
lysates from PTEN+/+, PTEN+/−, and PTEN−/− cells were resolved by reducing 10% SDS–PAG
MT1-MMP (Mr ~57–59 kDa). β-Actin was used as a loading control. Asterisk shows nonspethe three cell lines (Fig. 1B). Low levels of MT1-MMP were detected
in both PTEN+/+ and PTEN+/− cells. In contrast, PTEN−/− cells
exhibited signiﬁcantly higher amounts of MT1-MMP protein. Levels
of MT2-MMP protein could not be determined due to the unreliabil-
ity of the commercially available MT2-MMP antibodies when using
mouse cells. MT3-MMP protein was consistently undetectable in the
PTEN−/− cells in spite of up-regulation of mRNA and availability of
antibodies readily recognizing recombinant mouse MT3-MMP (data
not shown). It should bementioned that the lack of detection of MT3-
MMP protein is not unique to the mouse PTEN cellular system as we
have also found a similar lack of correlation between MT3-MMP
mRNA and protein expression results in multiple human and mouse
cell lines (manuscript in preparation). Taken together, these data
demonstrate that mouse prostate epithelial cells derived from PTEN
null prostate tumors exhibit a differential proﬁle of MMPs and TIMPs
with MT1-MMP being the major MT-MMP expressed upon loss of
PTEN. Furthermore, these data show that MT1-MMP-enhanced
expression in PTEN−/− cells is due to posttranscriptional regulation.
3.2. Enhanced MT1-MMP expression on the surface of PTEN−/− cells and
in extracts of PTEN null prostate tumors
Active MT1-MMP is displayed at the cell surface where it
accomplishes its proteolytic tasks. Therefore, we compared the levels
of MT1-MMP in PTEN+/+, PTEN+/−, and PTEN−/− cells by surface
biotinylation. As shown in Fig. 2A, a major form of biotinylated MT1-
MMP of ~57–58 kDa was detected in all three cell lines. However,
PTEN−/− PC cells displayed signiﬁcantly higher levels of surface MT1-
MMP (Fig. 2A, lane 5). No signal was observed in lysates of
nonbiotinylated cells (Fig. 2A, lanes 2, 4, and 6) demonstrating the
speciﬁcity of the detection.We also noticed a slight difference inMT1-
MMP electrophoretic migration between MT1-MMP forms expressed
by these cell lines with MT1-MMP in PTEN−/− cells showing a slightly
higher molecular weight. The mobility shift was clearly evident when
lysates of PTEN+/+ and PTEN−/− cells (Fig. 2B, lanes 1 and 2,
respectively) were electrophoresed side by side in 7.5% SDS–
polyacrylamide gels. The differences in MT1-MMP molecular weight
were also detected after immunoprecipitation of lysates with a pAb to
the cytosolic tail of MT1-MMP and detection with a mAb to the
catalytic domain (Fig. 2C).
Next, we examined the levels of expression ofMT1-MMP in normal
prostates from wild-type mice and prostate adenocarcinomas from
PTEN null mice. Immunohistochemistry was not reliable due to the
limitations of the anti-mouse MT1-MMP antibodies; therefore, we
performed immunoblot analyses of tissue extracts. This approach also
allowed for assessing possible differences in the molecular mass ofepithelial cells with different PTEN status. (A) Total RNA from PTEN+/+ (black bar) and
sequently real time PCR to quantify MT1-, MT2-, and MT3-MMPmRNA. Ct value of each
pendent experiments. *pb0.05; Student's t test. NS, not statistically signiﬁcant. (B) Cell
E followed by immunoblotting analysis using mAb 3G4 against the catalytic domain of
ciﬁc bands.
Fig. 2. Elevated surface expression of MT1-MMP in PTEN−/− cells. (A) PTEN+/+ (lanes 1
and 2), PTEN+/− (lanes 3 and 4), and PTEN−/− cells (lanes 5 and 6) were seeded on six-
well plates and incubated with (+) or without (−) cell-impermeable biotin for 30 min
on ice. Cell lysates from each cell were then incubated with avidin-conjugated beads,
and biotinylated proteins were resolved by reducing 10% SDS–PAGE followed by
immunoblot analysis using mAb 3G4. The same blot was reprobed with an antibody
against transferrin receptor (TFR), as a control. (B) Lysates from PTEN+/+ and PTEN−/−
cells were resolved by reducing 7.5% SDS–PAGE followed by immunoblotting analysis
using mAb 3G4. (C) Lysates from PTEN+/+ and PTEN−/− cells were immunoprecipi-
tated with pAb28209 to the cytosolic tail of MT1-MMP or nonimmune rabbit IgG and
protein-A-conjugated agarose beads. The immunoprecipitates were resolved by
reducing 7.5% SDS–PAGE followed by immunoblotting analysis using mAb 3G4.
Arrowheads on the right in panes B and C indicate the different species of MT1-MMP
detected. Asterisk shows nonspeciﬁc bands.
Fig. 3. Enhanced expression of MT1-MMP in lysates of wild-type and PTEN−/− mouse
prostate tissues. Mouse PTEN−/− prostate tumor (T1 and T2, lanes 4 and 6) and normal
(N1 and N2, lanes 3 and 5) prostate lysates from different mice and lysates from
cultured PTEN+/+ (lane 1) and PTEN−/− (lane 2) cells were resolved by reducing 8%
SDS–PAGE followed by immunoblot analyses using mAb 3G4 to the catalytic domain.
The antigen was detected using the TrueBlot™ ULTRA antibody against mouse IgG
followed by chemiluminescence. Asterisks show nonspeciﬁc bands.
Fig. 4. MT1-MMP is differentially O-glycosylated in PTEN+/+, PTEN+/−, and PTEN−/−
cells. PTEN+/+ (lanes 1 and 4), PTEN+/− (lanes 2 and 5), and PTEN−/− cells (lanes 3 and
6) were incubated with (+) or without (−) the O-glycosylation inhibitor BGN (2 mM)
for 48 h. The cells were then lysed, and the lysates were resolved by reducing 7.5% SDS–
PAGE followed by immunoblot analysis using the mAb 3G4. Arrowheads on the right
indicate the different species of MT1-MMP detected.
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depicted in Fig. 3 show that prostate tumors from PTEN null mice
contain signiﬁcantly higher levels of MT1-MMP than extracts from
normal prostates. Furthermore, as observedwith the isolated PTEN−/−
cells, tumor-associated MT1-MMP exhibits a slight increase in
molecular mass, which resembles that observed in MT1-MMP
expressed by PTEN−/− PC cells when resolved under the same
conditions (Fig. 3, lane 2). Therefore, the tumor results validated the
ﬁnding with the isolated prostate cells.
3.3. Differential MT1-MMP O-glycosylation and turnover in PTEN+/+
and PTEN−/− cells
Several possibilities may explain small differences in mobility shift
between MT1-MMP forms within the range of 57–60 kDa. These
include latent (60 kDa) vs. active species (57 kDa), O-glycosylation
and/or phosphorylation [3,7–9,40]. Because the available antibodies
to mouse MT1-MMP are directed to the catalytic domain (mAb 3G4)
or the cytosolic tail (pAb ab28209), immunoblot analyses were not
suitable to discriminate between latent and active MT1-MMP forms.
However, it is unlikely that the larger MT1-MMP form displayed by
PTEN−/− cells represents the latent species (~60 kDa) because
trafﬁcking to the cell surface has been shown to be coupled with
activation of the proform in the trans-Golgi network [41]. Previousstudies showed that MT1-MMP is O-glycosylated at four residues
(Thr291, Thr299, Thr300, and Ser301, human notation) locatedwithin the
hinge region [8], which are conserved in mouse MT1-MMP (data not
shown). Therefore, we hypothesized that PTEN+/+, PTEN+/−, and
PTEN−/− cells express different MT1-MMP glycoforms. To test this
hypothesis, the cell lines were treated with benzyl 2-acetamido-2-
deoxy-α-D-galactopyranoside (BGN). BGN is a competitive inhibitor
of galactosyltransferases and thus prevents addition of galactose to N-
acetyl-galactosamine moieties O-linked to serine and threonine
residues, thus blocking elongation of O-glycosyl chains. After BGN
treatment, the cell lysates were subjected to immunoblot analyses. As
shown in Fig. 4, MT1-MMP displayed by untreated PTEN−/− cells
(Fig. 4, lane 3) exhibits a higher molecular weight when compared to
PTEN+/+ and PTEN+/− cells (Fig. 4, lanes 1 and 2, respectively). BGN
treatment resulted in a mobility shift in MT1-MMP in all the cell lines.
However, the decrease in MT1-MMP molecular mass was more
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These data indicate that the higher molecular mass of MT1-MMP
displayed by PTEN−/− cells is due to differential O-glycosylation.
O-glycosylation of MT1-MMP's hinge region was postulated to
protect the active protease from autocatalytic cleavage within the
hinge region [7]. Consistently, reducedO-glycosylationwas associated
with enhanced degradation of the active MT1-MMP [7]. This
observation suggested the possibility that the high levels of MT1-
MMP detected in PTEN−/− cells were due in part to reduced
autocatalytic processing of the active protease and consequently
accumulation of enzyme at the cell surface. To test this hypothesis, we
measured the turnover of MT1-MMP in PTEN+/+ and PTEN−/− cells.
To this end, cells were treated with cycloheximide (CHX) to stop de
novo protein synthesis. At each time point after initiation of CHX
treatment, the cells were lysed, and the lysates were resolved by SDS–
PAGE followed by immunoblot analyses (Fig. 5A and C). The intensity
of the MT1-MMP band at each time was then quantiﬁed by
densitometry (Fig. 5B and D). These studies showed that MT1-MMP
protein levels decreased as a function of time in the presence of CHX
in both cell lines. However, MT1-MMP expressed by PTEN−/− cells
displayed a slower rate of turnover when compared to MT1-MMP
produced by PTEN+/+ cells, under the same experimental conditions
in two independent experiments. The rate of MT1-MMP turnover at
the cell surface is dictated in part by a balance between autocatalytic
processing and internalization [3]. However, the contribution of each
of these processes in regulating the levels of MT1-MMP in PTEN−/−
cells could not be determined. First, detection of the autocatalytic
degradation fragment of MT1-MMP was not possible because the
anticatalytic domain antibodies recognizing mouse MT1-MMP do notFig. 5. Reduced turnover of MT1-MMP in PTEN−/− cells. (A-D) PTEN+/+ and PTEN−/− cells w
and 8 h), the cells were lysed, and the lysates were resolved by reducing 10% SDS–PAGE follo
independent experiments. C and D show the results of the densitometry analyses, as describe
time point relative to time zero (100%).identify the 44-kDa processed form, which lacks the catalytic domain,
while the anticytosolic domain antibodies yielded nonspeciﬁc bands
overlapping the 44-kDa region and thus were unreliable. Second,
endocytosis studies of MT1-MMP in PTEN+/+ and PTEN−/− cells using
a reversible biotinylation assay were inconclusive due to the low
levels of internalized protease in particular in PTEN+/+ cells, which
display very low levels of surface MT1-MMP. Regardless, the data
shown here suggest that the enhanced surface expression of MT1-
MMP inmouse PTEN−/− prostate cancer cells is due in part to reduced
protease turnover.
3.4. Functional analyses of MT1-MMP-dependent activity
MT1-MMP is a major activator of pro-MMP-2 (pro-gelatinase A)
[42]. We therefore examined the expression and activation of pro-
MMP-2 in PTEN+/+ and PTEN−/− cells by gelatin zymography. As
shown in the zymogram of Fig. 6A, PTEN+/+ cells display no
detectable levels of gelatinases, in agreement with the PCR data. In
contrast, PTEN−/− cells express high levels of pro-MMP-2 and lower
levels of pro-MMP-9, under unstimulated conditions. As MT1-MMP-
dependent pro-MMP-2 activation usually requires stimulation with
the lectin ConA [43], the cells were treated with ConA and pro-MMP-2
activation was monitored by gelatin zymography of cell lysates. As a
reference, we used ﬁbrosarcoma HT1080 cells known to efﬁciently
activate pro-MMP-2 in response to ConA [43]. These studies showed
that ConA-treated PTEN−/− cells displayed a modest but readily
detectable processing of pro-MMP-2 to its active form of ~62 kDa in
(Fig. 6A). ConA treatment also induced expression but not activation
of pro-MMP-9 in PTEN−/− cells by an unknownmechanism. A limitedere incubated with 50 μg/ml of cycloheximide (CHX) for 8 h. At each time point (0, 2, 4,
wed by immunoblotting analysis using mAb 3G4. A and B show blots derived from two
d in Materials and methods. Values represent the relative amount of MT1-MMP at each
Fig. 6. Pro-MMP-2 activation, migration, and invasiveness of PTEN−/−cells. (A) Cultures of PTEN+/+, PTEN−/− , and HT1080 cells in six-well plates were untreated (−) or treated (+)
with ConA, and the lysates were subjected to gelatin zymography. P, pro-MMP-2 (~72 kDa); I, intermediate form of MMP-2 (~66 kDa); A, active MMP-2 (~62 kDa); Mo, mouse; Hu,
human. (B) Conﬂuent cultures of PTEN+/+ and PTEN−/− cells in six-well plates were scratched and incubated in complete media supplemented with 5 μg/ml mitomycin C for 8 h.
The cell monolayers were then photographed. (C) PTEN+/+ and PTEN−/− cells were seeded on top of a type I collagen gel in the presence or absence of BB-94. After 14 days, 5-μm-
thick frozen sections were stained with toluidine blue to identify the cells, indicated as black arrows. The experiments presented in panels A, B, and C were repeated at least three
times with similar results.
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cells even after ectopic expression of recombinant MT1-MMP or pro-
MMP-2 [18,44], suggesting that levels of expression are not the only
factor regulating MT1-MMP activity. It is also possible that MT1-MMP
O-glycosylation may affect the recruitment of TIMP-2 to the cell
surface and consequently compromise pro-MMP-2 activation [8].
MT1-MMP expression and activity have been linked to enhanced
tumor cell migration and invasion [6,13]. Therefore, we compared
the migratory and invasive activity of PTEN+/+ and PTEN−/− cells
using a scratch wound assay for cell migration and collagen I gels for
cell invasion. Migration assays showed that PTEN−/− cells were able
to close the gap in the scratched monolayer more efﬁciently than
PTEN+/+ cells after 8 h (Fig. 6B). Invasive activity was tested by
culturing PTEN+/+ and PTEN−/− cells atop gels of collagen I, as
described [13]. As shown in Fig. 6C, PTEN−/− cells readily invaded the
collagen I gel when compared to PTEN+/+ cells, under the same
conditions. This process was blocked by the broad-spectrum MMP
inhibitor, BB-94 (Fig. 6C) indicating an MMP-dependent process.
While BB-94 inhibits all members of theMMP family, includingMT1-MMP, we interpret the collagen-invasive of PTEN−/− cellsmost likely
as a result of MT1-MMP activity based on previous observations
indicating a dependence on MT1-MMP for invasion of collagen I
[13,45]. Moreover, these cells do not express soluble collagenases,
MT3-MMP or MT2-MMP (Supplemental Fig. 1), the latter also
implicated in collagen invasion (47).
3.5. The PI3K/AKT pathway regulates MT1-MMP expression in PTEN−/−
cells
Loss of PTEN results in deregulation of the PI3K/AKT and MAPK
pathways and their downstream effectors. To determine the role of
these pathways in MT-MMP (MT1-, MT2-, and MT3-MMP) expres-
sion, PTEN+/+ and PTEN−/− cells were treated with established
pharmacological inhibitors of PI3K, MAPK, AKT and mTOR. We
found that neither LY 294,002, PD 98,059, nor rapamycin treatment
had a signiﬁcant effect on MT-MMP mRNA expression levels in both
PTEN+/+ and PTEN−/− cells, as determined by semi-quantitative
PCR (Supplemental Fig. 2). We then examined the effects of these
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ses (Fig. 7). These studies showed that treatment with the MAPK
inhibitor PD 98,059 had no signiﬁcant effect on MT1-MMP protein
levels in both PTEN+/+ and PTEN−/− cells (Fig. 7A). In contrast,
inhibition of PI3K activity with LY 294,002 caused a dose-dependent
reduction of MT1-MMP protein level in PTEN−/− cells while in PTEN
+/+ cells reduction of MT1-MMP was only evident at an inhibitor
concentration of 50 μM (Fig. 7B). Treatment with AKT inhibitor IV, a
cell-permeable benzimidazole compound that inhibits activation of
all AKT isoforms, also reduced MT1-MMP protein levels in both cell
lines at doses of 5 μM (Fig. 7C). As expected, this inhibitor caused a
marked decrease in pAKT (Fig. 7C). One of the downstream targets
of activated AKTs is mTOR, a phosphoinositide-3-kinase-related
kinase that is a component of the mTOR complex 1 (mTORC1) and 2
(mTORC2) [46]. Once activated, mTORC1 promotes protein synthe-
sis and consequently cell growth and proliferation via phosphory-
lation of the translational regulators 4E-BP and 40S ribosomal
protein S6 kinases [47]. To examine the role of mTORC1 in
regulation of MT1-MMP expression, PTEN+/+ and PTEN−/− cells
were treated with rapamycin, a known pharmacological inhibitor ofFig. 7. Effect of pharmacological inhibitors to PI3K, AKT, MAPK, and mTOR on MT1-MMP exp
without (−) the indicated doses of either PD 98,059 (A), LY 294,002 (B), Akt inhibitor IV (C),
(−) or treated (+) with either LY 294,002 or PD 98,059 for 18 h. Then, the cultures received
period, the cells were lysed, and the lysates were resolved by reducing 10% SDS–PAGE foll
panels A–E were repeated at least three times with similar results.mTORC1. Immunoblot analyses showed that rapamycin treatment
completely inhibited S6K phosphorylation in both cell lines at the
doses used here (5 and 10 μM), consistent with mTOR inhibition
(Fig. 7D). Surprisingly, rapamycin treatment signiﬁcantly increased
the levels of MT1-MMP protein in PTEN−/− cells while had minimal
effect in PTEN+/+ cells (Fig. 7D). As shown in Supplemental Fig. 2,
rapamycin treatment had no signiﬁcant effect on MT1-MMP mRNA
levels in both cell lines when compared to untreated cells,
suggesting a posttranslational effect of rapamycin on MT1-MMP
regulation. Previous studies demonstrated that rapamycin treat-
ment induced activation of survival pathways via PI3K activity in
cancer cells by a feedback mechanism [48]. Therefore, we examined
the effects of rapamycin on MT1-MMP protein levels in the absence
or presence of LY 294,002 or PD 98,059 in PTEN−/− cells. These
studies showed that administration of rapamycin in the presence of
LY 294,002 (Fig. 7E, lane 5), but not PD 98,059 (Fig. 7E, lane 6),
inhibited rapamycin-induced expression of MT1-MMP (Fig. 7E, lane
4). Thus, PI3K activity is required for the up-regulation of MT1-MMP
protein levels caused by rapamycin treatment in PTEN−/− cells.
Taken together these results suggest a role for the PI3K/AKTression. Serum-starved PTEN+/+ and PTEN−/− cells were incubated (18 h) with (+) or
or rapamycin (D) in serum-freemedia. (E) Serum-starved PTEN−/− cells were untreated
rapamycin (+) or vehicle (−) and were incubated for 18 h. At the end of the incubation
owed by immunoblot analyses with the appropriate antibodies. The data presented in
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prostate cancer PTEN+/+ cells.
4. Discussion
Conditional biallelic deletion of PTEN in mouse prostate
epithelium leads to the development of PC in a process that
resembles the spectrum of pathological stages observed in human
PC, including development of invasive and metastatic adenocarci-
noma. Inactivation of PTEN in these particular mouse models can
therefore initiate a cascade of genetic and epigenetic events that
results in the expression of a malignant phenotype that ultimately
leads to tumor cell dissemination. It should be noted, however, that
distant metastasis in these models is rather limited and the tumors
fail to develop skeletal metastasis [49,50], a characteristic of
advanced PC in human patients. Nonetheless, in spite of their
inherent limitations, PTEN mouse models of PC provide an
opportunity to examine the relationship between PTEN loss and
genes known to be associated with tumor cell invasion. In this
study, prostate tumors and cell lines derived from mice bearing a
prostate-speciﬁc deletion of PTEN [33] and from wild-type mice
were used to investigate the expression of MMPs associated with
cancer progression including gelatinases, MT1-MMP and its closely
homologues MT2-and MT3-MMP. In particular, the MT-MMPs were
shown to confer migratory and invasive activity to cancer cells
[12,39], and therefore may play a role in the invasive phenotype of
PTEN null prostate tumors. Our data show that PTEN null PC cells
display up-regulation of MT1-MMP, MT3-MMP, and gelatinases
gelatinase expression, suggesting that this protease proﬁle may
contribute to their malignant behavior. In addition, loss of PTEN was
associated with enhanced protein expression of MT1-MMP in vivo.
We also noticed that the molecular mass of MT1-MMP displayed by
PTEN null tumors and isolated cells was slightly but consistently
higher than that found in wild-type prostate tissues and their
isolated epithelial cells. Studies with an O-glycosylation inhibitor
indicated that the differences in molecular mass were consistent
with differential O-glycosylation of MT1-MMP between wild-type
and PTEN null cells. Although not directly proven here, differential
O-glycosylation is also likely to explain the mass differences in MT1-
MMP observed in vivo. Nonetheless, to our knowledge, this is the
ﬁrst study to show a differential O-glycosylation of MT1-MMP that
is associated with a loss of PTEN function in mouse prostate
epithelial cells.
Posttranslational modiﬁcation of MT1-MMP by O-linked glyco-
sylation occurs at residues present within the hinge region [8], a
stretch of 32 residues that link the active site with the hemopexin-
like domain. Previous studies have shown that the hinge of MT1-
MMP is highly susceptible to proteolysis, a process that has been
postulated to be due to its amino acid composition and structural
features [51]. Consistently, O-glycosylation of the hinge has been
shown to regulate MT1-MMP stability, possibly by restricting its
susceptibility to proteolytic attack [8]. Here we found that the
differential O-glycosylation of MT1-MMP observed in PTEN−/− and
PTEN+/+ cells is associated with a slower turnover of active protease
in the cancer cells, consistent with a role for O-linked carbohydrates
in controlling MT1-MMP stability, possibly by decreasing the rate of
enzyme autolysis [7]. This observation suggests that O-glycosylation
contributes to the high levels of MT1-MMP found at the surface of
PTEN−/− cells which in turns results in enhanced pro-MMP-2
activation , migration, and invasion, three cellular activities known
to require MT1-MMP activity [4,13,37]. Collectively, these data
uncover a novel relationship between the loss of a powerful tumor
suppressor gene, PTEN, and a key posttranslational modiﬁcation, O-
glycosylation, of a cancer-relevant protease, MT1-MMP, which can
partly explain the association between PTEN loss and PC progression.
It is tempting to speculate that the ﬁndings with MT1-MMP mayreﬂect a general alteration in protein glycosylation as a consequence
of PTEN loss of function. If so, it will be interesting to investigate
whether PTEN inactivation in cancer cells, directly or indirectly,
regulates the expression and function of glycosyltransferases, and
consequently alters the proﬁle of the cellular glycome [52]. Such
potential alterations in glycosylation may have a profound impact in
tumor cell behavior by regulating the function of cancer relevant
proteins.
It is well established that loss of PTEN results in activation of the
PI3K/AKT pathway and downstream effectors leading to cancer cell
survival and expression of the malignant phenotype. Here we found
that pharmacological inhibition of PI3K activity and Akt activation
but not inhibition of MAPK decreased the level of MT1-MMP protein
in mouse PTEN−/− prostate cancer cells. These results are consistent
with previous studies that suggested a role for PI3K activity in
regulation of MT1-MMP expression in both normal and cancer cells
including prostate cancer cells [53–58]. While our data suggest that
in PTEN−/− cells PI3K and AKT activity is directly involved in the
regulation of MT1-MMP protein levels, inhibition of these kinases
did not alter the molecular mass of MT1-MMP. This ﬁnding suggests
that changes in O-glycosylation upon loss of PTEN in this mouse
system are likely to be the result of secondary genetic alterations
that cannot be overridden by direct inhibition of PI3K and AKT
activity. The role of AKT in regulation of MT1-MMP is further
evidenced by the phenotype of mice lacking AKT1, which exhibit
dwarﬁsm and alterations in skeletal development that resemble the
bone phenotype of MT1-MMP null mice [59]. Moreover, delayed
secondary ossiﬁcation in AKT1 null mice has been ascribed to
reduced expression of active MT1-MMP [60]. Taken together, these
observations place the PI3K/AKT pathway as a master regulator of
MT1-MMP expression during bone development. Thus, given the
role of AKT in the regulation of MT1-MMP expression in cancer cells,
AKT activation in PC patients bearing PTEN mutations may
contribute to the development of skeletal metastasis through an
MT1-MMP-dependent process [14].
The PI3K/AKT pathway indirectly and directly activates mTORC1,
which in turn positively regulates the translational machinery and
thus promotes protein synthesis [61–63]. This suggests that mTORC1
activation, as a consequence of PTEN loss, may be behind the enhanced
levels of MT1-MMP protein displayed by PTEN−/− cells. In this regard,
it was interesting to ﬁnd that rapamycin, a speciﬁc mTOR inhibitor,
increased rather than decreased MT1-MMP protein in PTEN−/− cells
and had no apparent effect on the molecular mass of MT1-MMP.
Unanticipated effects of rapamycin-mediated inhibition of mTOR in
cancer cells have been reported [46]. For instance, rapamycin induces
activation of multiple survival pathways including the PI3K/AKT
pathway in various human cancer cell lines by a feedback mechanism
[48,64–68]. In addition, rapamycin was shown to induce the
expression of Her2 and insulin growth factor receptor 1 in
gastrointestinal cells [69]. In mouse PTEN−/− PC cells, the rebound
effect of rapamycin treatment may lead to the activation of alternate
pathways that augments MT1-MMP protein [70]. Our data show that
PI3K but not MAPK inhibition blocks the rapamycin-induced
expression of MT1-MMP in PTEN−/− cells, consistent with the
reported effects of rapamycin on the PIK3/AKT pathway [70]. At
present, the speciﬁc effectors and/or mechanisms mediating the up-
regulation of MT1-MMP protein levels in rapamycin-treated PTEN−/−
cells remain to be elucidated and are under investigation. Although
cancers are genetically and molecularly heterogeneous and rapamy-
cin effects are context-dependent, our data nonetheless unveil a
potential side effect from mTOR inhibition in the context of PTEN
inactivation that deserves further exploration, as up-regulation of
MT1-MMP expression may be counterproductive. Given the critical
role that MT1-MMP plays in tumor invasion and the therapeutic
potential of targetingmTOR, more studies are warranted to determine
the effects of rapamycin or other mTOR inhibitors on the regulation of
1296 S. Kim et al. / Biochimica et Biophysica Acta 1803 (2010) 1287–1297this key protease in several cancers. The results of these studies may
have an impact in the development of therapies targeting comple-
mentary pathways including mTOR for more effective clinical
responses [71]. In summary, the present studies demonstrate a
differential regulation of MMP expression proﬁle in cell lines
established from prostates of wild-type and PTEN null mice.
Speciﬁcally, PTEN loss in this mouse model is associated with
posttranslational up-regulation and differential O-glycosylation of
MT1-MMP. This ﬁnding unveils a novel effect of PTEN deregulation on
the function of a tumor-associated protease that may partly explain
the impact of PTEN loss in cancer progression.
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